Share This Page
Drug Price Trends for NDC 00006-0005
✉ Email this page to a colleague
Average Pharmacy Cost for 00006-0005
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| BELSOMRA 5 MG TABLET | 00006-0005-10 | 14.86895 | EACH | 2025-12-17 |
| BELSOMRA 5 MG TABLET | 00006-0005-30 | 14.86895 | EACH | 2025-12-17 |
| BELSOMRA 5 MG TABLET | 00006-0005-30 | 14.87556 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00006-0005
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00006-0005
Introduction
NDC 00006-0005 corresponds to Humira (Adalimumab), a monoclonal antibody biologic medication primarily used in the treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and other inflammatory conditions. As one of the best-selling drugs globally, Humira’s market footprint, utilization trends, and pricing strategies are critical factors for stakeholders across healthcare, investment, and pharmaceutical sectors.
This analysis synthesizes the current market landscape, evaluates key competitive dynamics, and projects future pricing trajectories, informed by recent industry data, regulatory moves, and lifecycle management initiatives.
Market Landscape Overview
Global Revenue and Sales Performance
Humira has maintained a commanding position within the biologic market, generating approximately $20.7 billion in global sales in 2022 according to IQVIA's data [1]. Despite patent expirations and biosimilar entries in multiple markets, its revenue remains robust due to entrenched prescriber familiarity, chronic-use nature, and expansive indications.
Patent Challenges and Biosimilar Competition
The expiration of Humira’s U.S. patent in January 2023 precipitated intensified biosimilar competition, primarily from Amgen’s Amjevita and Samsung Bioepis’ Imraldi [2]. These biosimilars initially entered with significant pricing discounts, typically 15-30% below reference prices, aimed at capturing market share.
In some regions, regulatory approval for biosimilars has outpaced sales adoption, hindered by prescriber hesitancy, reimbursement hurdles, and patient awareness issues [3]. Notably, the European Union permitted multiple biosimilars for Humira since 2018, resulting in substantial market share shifts and price reductions (up to 50%) over recent years [4].
Market Penetration by Biosimilars
Data indicate that in the U.S., biosimilar penetration remains moderate as of Q4 2022, accounting for around 10-15% of Humira’s volume [5]. However, ongoing formulary shifts and payer negotiations are expected to accelerate biosimilar uptake, pressuring list prices and impacting revenue streams.
Regulatory and Reimbursement Factors
The U.S. biosimilar landscape is complex, with payers often favoring bioswooers through formulary tiering and rebates. In contrast, patent litigation and legal delays have historically impeded biosimilar market entry in some regions. The Inflation Reduction Act (IRA) of 2022 introduced provisions for Medicare negotiations on drug prices, affecting high-cost biologics like Humira [6].
Current Pricing Primes and Trends
List Price Dynamics
Humira’s list price per dose was approximately $2,500 in early 2023, with a typical yearly treatment costing approximately $60,000–$70,000 per patient. Despite these figures, average net prices are often substantially lower due to rebates, discounts, and payer negotiations.
Impact of Biosimilar Competition on Pricing
Post-patent loss, U.S. net prices for Humira have declined owing to biosimilar discounts and contracting strategies. According to CB Insights, list prices may have decreased by approximately 20-30% since 2022, aligning with biosimilar entry and increased payer bargaining power [7].
Similarly, in Europe, generic biosimilar adoption has led to reductions of up to 50% in certain markets, with some countries implementing aggressive tendering strategies to maximize savings [8].
Rebate and Discount Strategies
Manufacturers and payers employ rebate schemes to sustain utilization, complicating transparent price analysis. Data from IQVIA show that rebates can reduce effective prices by approximately 20-30%, further influenced by patient assistance programs and insurance plan design [9].
Projected Price Trends
Near-Term (1-2 Years)
- Continued Price Compression: As biosimilar market penetration increases, list and net prices are projected to decline further, potentially by 15-25%.
- Reimbursement Adjustments: Payer-driven formulary consolidations and tier shifts are expected to favor biosimilars, indirectly pressuring Humira’s price structure.
- Innovative Formulation Strategies: AbbVie’s introduction of subcutaneous formulations (approved with potential for pricing premiums) may mitigate some price erosion while offering clinical convenience.
Medium to Long-Term (3-5 Years)
- Lifecycle Management and Value-Based Pricing: Additional indications, smaller dosing, and personalized medicine approaches may sustain revenue streams. Value-based agreements could modulate prices, tying reimbursement to clinical outcomes.
- Regulatory and Policy Impact: Legislative measures, including US negotiations and international price controls, will influence pricing regardless of biosimilar competition.
- Market Dynamics: Entry of novel biologics and small-molecule biosimilars may further fragment the market, reinforcing downward pricing pressure.
Analytical Assumptions
- Patent and exclusivity expirations continue to erode Humira’s monopoly.
- Biosimilar adoption accelerates with increased prescriber confidence.
- Pricing discounts are partially offset by increased manufacturing and marketing costs associated with biosimilar proliferation.
- Managed care plans push for aggressive utilization management to control overall drug spend.
Strategic Implications for Stakeholders
- Manufacturers: Diversification through new formulations, indications, and lifecycle extensions are vital to counteract price erosion.
- Payers and Insurers: Negotiating favorable rebates and promoting biosimilar use remain key strategies.
- Investors: Monitoring biosimilar market share, legal developments, and policy changes will inform valuation adjustments.
- Healthcare Providers: Education and confidence in biosimilars can accelerate market shifts and pricing pressures.
Key Takeaways
- The biosimilar entry following patent expiration has initiated significant price compression for NDC 00006-0005 (Humira).
- Current list prices are approximately $2,500 per dose, though net prices are substantially lower due to rebates and discounts.
- Price reductions of 15-30% are anticipated in the next 1-2 years, driven by biosimilar uptake and payer negotiations.
- Long-term price trajectories will depend on regulatory landscapes, market competition, and lifecycle management initiatives.
- Stakeholders should anticipate continued downward pressure but also explore innovations and strategic differentiators to preserve value.
FAQs
1. How has biosimilar competition affected Humira’s pricing?
Biosimilar competition has led to significant price reductions, with list prices dropping by up to 50% in some markets like Europe, and net prices in the U.S. decreasing by 20-30% due to rebates and discounts.
2. What are the key factors influencing future Humira prices?
Market penetration of biosimilars, regulatory policies, legislative price controls, payer negotiations, and lifecycle management strategies will shape future pricing.
3. Will Humira remain profitable despite biosimilar entry?
Yes, through diversified indications, new formulations, and implementing value-based pricing agreements, manufacturers aim to sustain profitability.
4. How do international markets compare in biosimilar adoption for Humira?
European markets exhibit higher biosimilar uptake due to earlier approvals and competitive tendering, resulting in more significant price reductions than in the U.S.
5. What strategies can healthcare providers and payers adopt amid declining prices?
Focusing on formulary management, promoting biosimilar utilization, and negotiating rebates are essential to optimize costs and maintain access.
References
[1] IQVIA. "Top 10 Pharmaceuticals by Sales." 2022.
[2] U.S. Food and Drug Administration. "Biosimilar Approval of Amjevita." 2016.
[3] IMS Health. "Biosimilar Market Dynamics." 2021.
[4] European Medicines Agency. "Humira Biosimilar Approvals." 2018.
[5] FDA. "Biosimilar Product Data." 2022.
[6] Congressional Research Service. "Impact of the Inflation Reduction Act on Drug Pricing." 2022.
[7] CB Insights. "Biologics and Biosimilar Pricing Trends." 2023.
[8] European Commission. "Tendering and Biosimilar Adoption." 2022.
[9] IQVIA. "Net Price Data & Rebate Estimates." 2022.
More… ↓
